A Phase 2 interventional study of Sertraline in Coccidioidomycosis, sponsored by University of California, San Francisco. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-21.
Sponsored by University of California, San Francisco · Phase 2, Interventional, and Treatment
In this study patients will be randomized 1:2 to receive either standard of care treatment or standard of care + Sertraline 200mg/day for 2 weeks, then 400 mg/day for 50 weeks for treatment of disseminated and meningeal coccidioidomycosis.
Sertraline has been demonstrated to have in-vitro activity against coccidioides, and in-vivo activity against cryptococcal meningitis in clinical trials. Disseminated and meningeal coccidiodes infections require lifelong treatment, have poor outcomes, and new treatment options are needed. In this study the investigators will determine safety and tolerability of adjunctive sertraline (grade 4-5 adverse reactions) compared to standard coccidioidomycosis therapy alone.
25 studies on the registry are indexed under Coccidioidomycosis; 5 are open to participants now.
Browse Coccidioidomycosis studies →University of California, San Francisco is the lead sponsor of 2,132 studies on the registry; 375 are open to participants now.
Of its 262 completed or terminated interventional studies of FDA-regulated products, 196 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Severe coccidioidomycosis infection, manifest as by one of:
Exclusion Criteria:
Pregnancy
standard of care treatment for disseminated or meningeal coccidioidomycosis
Standard of care treatment with the addition of sertraline for the treatment of disseminated or meningeal coccidioidomycosis
Drug: Sertraline
400 mg/day sertraline
Adverse Reactions
grade 4-5 adverse reactions
Time frame: 2 years
Mycoses Study Group Score
scoring of clinical outcomes
Time frame: 2 years
Depression Screening
Patient Health Questionnaire 9
Time frame: 2 years
Functional Assessment
Karnofsky
Time frame: 2 years
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco